ArticleBreast (Edinburgh, Scotland)2025

Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.

Matheus de Oliveira Andrade et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.